Drug Profile
NGM 395
Alternative Names: NGM395Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator NGM Biopharmaceuticals
- Class Cytokines; Hepatoprotectants; Hormones; Obesity therapies
- Mechanism of Action Glial cell line-derived neurotrophic factor receptor agonists; Growth differentiation factor 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic fatty liver disease; Obesity
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease in Australia (SC, Injection)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Obesity in Australia (SC, Injection)
- 19 Jul 2021 NGM Biopharmaceuticals completes a phase I trial in Non-alcoholic fatty liver disease and Obesity in Australia (SC)(NCT04187339)